Sai Life Sciences investing Rs 450 crore in Hyderabad by 2023
This investment is a part of an organisational transformation initiative (Sai Nxt), where the company is investing $150 million (over Rs 1,000 crore) in the period between 2019 and 2023
Hyderabad: Hyderabad-based Sai Life Sciences, a contract research, development & manufacturing organisation, is investing about Rs 450 crore at its integrated research and development (R&D) campus in Hyderabad by 2023. This 13-acre R&D campus houses over 1,200 employees.
This investment is a part of an organisational transformation initiative (Sai Nxt), where the company is investing $150 million (over Rs 1,000 crore) in the period between 2019 and 2023, to expand and upgrade its R&D and manufacturing facilities, induct global scientific and leadership talent, strengthen automation and data systems.
Krishna Kanumuri, CEO & MD, Sai Life Sciences, told Telangana Today, “The company is primarily focusing its investments on three key areas-people & culture, processes & automation, and infrastructure & scientific capabilities.”
The company opened its 83,000 sq ft research and technology (R&T) centre in Hyderabad last August, augmenting its research capabilities and advanced technology platforms. This centre has 24 chemistry labs with analytical labs, fully equipped technology suite and a dedicated process safety lab.
To further build its capabilities in biology, Sai Life Sciences recently set up a 75,000 sq ft discovery biology facility at its Hyderabad campus. “We have 1,200 plus employees at the Hyderabad R&D campus, of which 120 are part of the biology vertical. We expect this number to go up to 170 by the end of this year,” Kanumuri said.
The facility, which expands its in vivo (studying living organisms) and in vitro (studying microorganisms or human or animal cells) services, augments both its capabilities and capacity to deploy platforms and technologies for accelerating its integrated drug discovery programmes. He added, “The new facility marks the culmination of a journey we began two years ago, of creating differentiated value for our discovery clients through an integrated delivery model across Boston and Hyderabad.”
Global facilities
The company’s first international R&D facility (with a biology lab) that began operations in 2019 in Boston, USA, offers startups and biotech companies services to address exploratory and custom biology needs. Encouraged by the initial success with the Boston-Hyderabad integrated model, Sai Life Sciences plans to expand its capacity at both locations in the coming months.
Sai Life Sciences’ Manchester (UK) site, located in the Alderley Park lifesciences ecosystem, enables the UK and EU based pharmaceutical and biotech companies to have easier collaboration with its scientists as well as with the US-based clients due to reduced time zone differences.
The company’s discovery services support global innovator companies — from startups to large pharma companies, across therapeutic areas such as oncology, central nervous system, antivirals, and inflammation.
Now you can get handpicked stories from Telangana Today on Telegram everyday. Click the link to subscribe.
Click to follow Telangana Today Facebook page and Twitter .
Related News
